|
US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US4844893A
(en)
|
1986-10-07 |
1989-07-04 |
Scripps Clinic And Research Foundation |
EX vivo effector cell activation for target cell killing
|
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
|
US5124263A
(en)
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
ATE145428T1
(de)
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
|
EP0585257A4
(en)
|
1991-03-28 |
1995-02-22 |
Univ Minnesota |
DNA AND AMINO ACID SEQUENCE SPECIFIC TO NATURAL K KILLER CELLS.
|
|
WO1994026290A1
(en)
|
1993-05-07 |
1994-11-24 |
Immunex Corporation |
Cytokine designated 4-1bb ligand and human receptor that binds thereto
|
|
WO1995007358A1
(en)
|
1993-07-30 |
1995-03-16 |
University Of Medicine & Dentistry Of New Jersey |
Efficient gene transfer into primary lymphocytes
|
|
US5653977A
(en)
|
1993-09-09 |
1997-08-05 |
Uab Research Foundation |
Anti-idiotypic antibody that mimics the GD2 antigen
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
DE19520729A1
(de)
|
1995-06-07 |
1996-12-12 |
Orpegen Pharma Gmbh |
Testsystem zur Erfassung der Aktivität von NK-Zellen
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US7070771B1
(en)
|
1996-12-09 |
2006-07-04 |
Regents Of The University Of California |
Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
|
|
US20020018783A1
(en)
|
1997-03-20 |
2002-02-14 |
Michel Sadelain |
Fusion proteins of a single chain antibody and cd28 and uses thereof
|
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
|
PT1003861E
(pt)
|
1997-08-01 |
2007-01-31 |
Schering Corp |
Proteínas de membrana de células de mamíferos;reagentes relacionados
|
|
GB9725764D0
(en)
|
1997-12-04 |
1998-02-04 |
Isis Innovation |
HLA-E binding
|
|
CA2318372C
(en)
|
1998-02-02 |
2008-08-19 |
Johns Hopkins University School Of Medicine |
A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
|
|
DE19813759C1
(de)
|
1998-03-27 |
1999-07-15 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6361998B1
(en)
|
1998-06-25 |
2002-03-26 |
Hemosol Inc. |
Efficient culture of stem cells for the production of hemoglobin
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
AU4418900A
(en)
|
1999-04-16 |
2000-11-02 |
Celltech Therapeutics Limited |
Synthetic transmembrane components
|
|
AU7954500A
(en)
|
1999-10-21 |
2001-04-30 |
Yuji Ohkubo |
Method of in vitro culture of lymphocytes and gene therapy compositions
|
|
JP3619853B2
(ja)
|
1999-11-26 |
2005-02-16 |
独立行政法人理化学研究所 |
ナチュラルキラー細胞の増殖方法
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
JP2002045174A
(ja)
|
2000-07-31 |
2002-02-12 |
Inst Of Physical & Chemical Res |
ナチュラルキラー細胞増殖法
|
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20030129649A1
(en)
|
2001-04-24 |
2003-07-10 |
Kobilka Brian K. |
Conformational assays to detect binding to G protein-coupled receptors
|
|
ATE429486T1
(de)
|
2001-08-15 |
2009-05-15 |
Takara Bio Inc |
Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
|
|
US7763243B2
(en)
|
2001-08-17 |
2010-07-27 |
Roger Williams Medical Center |
In situ immunization
|
|
AU2003202908A1
(en)
|
2002-01-03 |
2003-07-24 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
CA2483343A1
(en)
|
2002-04-22 |
2003-10-30 |
Fred Hutchinson Cancer Research Center |
Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
WO2004027036A2
(en)
|
2002-09-19 |
2004-04-01 |
Johns Hopkins University School Of Medicine |
Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
|
|
GB0225279D0
(en)
|
2002-10-30 |
2002-12-11 |
Celltech R&D Ltd |
Biological products
|
|
US9068234B2
(en)
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
CA2530349A1
(en)
|
2003-06-27 |
2005-01-06 |
Dnavec Research Inc. |
Method for transplanting lymphohematopoietic cells into mammal
|
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
CA2568344C
(en)
|
2004-05-27 |
2016-01-19 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
PL2921500T3
(pl)
|
2004-07-10 |
2024-02-05 |
The Institute For Cancer Research |
Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
|
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
|
GB0426903D0
(en)
|
2004-12-08 |
2005-01-12 |
Alexis Biotech Ltd |
Complexes and methods
|
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
EP1945771A1
(en)
|
2005-10-28 |
2008-07-23 |
Novo Nordisk A/S |
Fusion proteins that bind effector lymphocytes and target cells
|
|
US20070160578A1
(en)
|
2005-12-14 |
2007-07-12 |
The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services |
Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
|
|
ATE555383T1
(de)
|
2006-06-22 |
2012-05-15 |
Novo Nordisk As |
Lösliche heterodimere rezeptoren und ihre verwendung
|
|
PL2856876T3
(pl)
|
2007-03-30 |
2018-06-29 |
Memorial Sloan-Kettering Cancer Center |
Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
|
|
WO2009117566A1
(en)
|
2008-03-21 |
2009-09-24 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Chemokine gene-modified cells for cancer immunotherapy
|
|
US8822647B2
(en)
*
|
2008-08-26 |
2014-09-02 |
City Of Hope |
Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
|
|
CN101684456A
(zh)
|
2008-09-28 |
2010-03-31 |
江门罗森生物制药有限公司 |
一种体外培养条件下扩增人nk细胞的方法
|
|
WO2010071836A1
(en)
|
2008-12-19 |
2010-06-24 |
Inserm |
Il-15 mediated nk and t cell maturation
|
|
EP2411507B1
(en)
|
2009-03-26 |
2019-09-25 |
CellProtect Nordic Pharmaceuticals AB |
Expansion of nk cells
|
|
EP3135294B1
(en)
|
2009-08-14 |
2020-06-03 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Use of il-15-il-15 receptor heterodimers to treat lymphopenia
|
|
EP2493485A1
(en)
|
2009-10-30 |
2012-09-05 |
University Of Arkansas For Medical Science |
Use of autologous effector cells for treatment of multiple myeloma
|
|
WO2011053322A1
(en)
|
2009-10-30 |
2011-05-05 |
University Of Arkansas For Medical Science |
Use of autologous effector cells and antibodies for treatment of multiple myeloma
|
|
MX337600B
(es)
|
2009-12-02 |
2016-03-11 |
Imaginab Inc |
Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso.
|
|
US20130011376A1
(en)
|
2009-12-29 |
2013-01-10 |
Gamida Cell Ltd. |
Methods for Enhancing Natural Killer Cell Proliferation and Activity
|
|
JP5916718B2
(ja)
|
2010-06-04 |
2016-05-11 |
ビオメリューＢｉｏｍｅｒｉｅｕｘ |
結腸直腸癌の予後判定のための方法及びキット
|
|
KR20180099915A
(ko)
|
2010-07-13 |
2018-09-05 |
안트로제네시스 코포레이션 |
천연 킬러 세포의 생성 방법
|
|
EP2614077B1
(en)
|
2010-09-08 |
2016-08-17 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Chimeric antigen receptors with an optimized hinge region
|
|
WO2012136231A1
(en)
|
2010-09-08 |
2012-10-11 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Interleukin 15 as selectable marker for gene transfer in lymphocytes
|
|
EP2619229B1
(en)
|
2010-09-21 |
2016-04-06 |
Altor BioScience Corporation |
Multimeric il-15 soluble fusion molecules and methods of making and using same
|
|
BR112013012138B1
(pt)
|
2010-11-22 |
2022-02-22 |
Innate Pharma Sa |
Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US20120321666A1
(en)
|
2011-05-23 |
2012-12-20 |
Cooper Laurence J N |
T cell therapy for b cell lymphoma
|
|
US10421960B2
(en)
|
2011-09-16 |
2019-09-24 |
The Trustees Of The University Of Pennsylvania |
RNA engineered T cells for the treatment of cancer
|
|
EP2755487B1
(en)
|
2011-09-16 |
2018-12-19 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
JP6066356B2
(ja)
|
2011-09-23 |
2017-01-25 |
ブルーバード バイオ， インコーポレイテッド |
改善された遺伝子治療方法
|
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
CN103294374A
(zh)
|
2012-02-23 |
2013-09-11 |
中兴通讯股份有限公司 |
一种触摸屏解锁方法及装置
|
|
CN104750498B
(zh)
|
2012-02-24 |
2018-12-18 |
青岛海信电器股份有限公司 |
一种控制鼠标模块的方法及电子设备
|
|
EP4279579A3
(en)
|
2012-06-28 |
2024-02-21 |
University Of Central Florida Research Foundation Incorporated |
Methods and compositions for natural killer cells
|
|
US20160235787A1
(en)
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
|
WO2014022826A2
(en)
|
2012-08-03 |
2014-02-06 |
Icahn School Of Medicine At Mount Sinai |
Biomarker associated with risk of melanoma reoccurrence
|
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
|
WO2014055413A2
(en)
|
2012-10-02 |
2014-04-10 |
Bloodcenter Research Foundation |
A method of providing cellular therapy using modified natural killer cells or t lymphocytes
|
|
SG11201502598SA
(en)
|
2012-10-02 |
2015-05-28 |
Sloan Kettering Inst Cancer |
Compositions and methods for immunotherapy
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
WO2014099671A1
(en)
|
2012-12-20 |
2014-06-26 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
|
WO2014117121A1
(en)
|
2013-01-28 |
2014-07-31 |
St. Jude Children's Research Hospital, Inc. |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
SI3300745T1
(sl)
|
2013-02-15 |
2020-01-31 |
The Regents Of The University Of California |
Himerni antigenski receptor in postopki njihove uporabe
|
|
BR112015020516A2
(pt)
|
2013-02-26 |
2017-10-10 |
Memorial Sloan Kettering Cancer Center |
composições e métodos para imunoterapia
|
|
CN103113470B
(zh)
|
2013-02-27 |
2015-04-22 |
四川大学 |
靶向人egfr的基因工程化淋巴细胞及其制备方法和用途
|
|
EP3241897B1
(en)
|
2013-03-07 |
2018-10-03 |
Baylor College of Medicine |
Targeting cd138 in cancer
|
|
HK1220614A1
(zh)
|
2013-03-10 |
2017-05-12 |
Baylor College Of Medicine |
耐化疗免疫细胞
|
|
JP6857028B2
(ja)
|
2013-03-15 |
2021-04-14 |
メモリアル スローン ケタリング キャンサー センター |
免疫治療のための組成物および方法
|
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
EP2986636B1
(en)
|
2013-04-17 |
2018-11-14 |
Baylor College Of Medicine |
Immunosuppressive tgf-beta signal converter
|
|
EP3974520A1
(en)
|
2013-05-14 |
2022-03-30 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
ES2897579T3
(es)
|
2013-06-10 |
2022-03-01 |
Dana Farber Cancer Inst Inc |
Métodos y composiciones para reducir la inmunosupresión por células tumorales
|
|
WO2015015791A1
(ja)
|
2013-07-31 |
2015-02-05 |
キヤノン株式会社 |
磁性トナー
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
WO2015058018A1
(en)
|
2013-10-17 |
2015-04-23 |
National University Of Singapore |
Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
|
|
AU2014342020C1
(en)
|
2013-10-31 |
2019-09-05 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
|
|
MX377283B
(es)
|
2013-11-21 |
2025-03-07 |
Ucl Business Ltd |
Célula t o nk que coexpresa un receptor antigénico quimérico (car).
|
|
WO2015092024A2
(en)
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
AU2014368892B2
(en)
|
2013-12-20 |
2019-06-13 |
Fred Hutchinson Cancer Center |
Tagged chimeric effector molecules and receptors thereof
|
|
US20160333108A1
(en)
|
2014-01-13 |
2016-11-17 |
Stephen J. Forman |
CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
|
|
US20170015975A1
(en)
|
2014-02-10 |
2017-01-19 |
Nvigen, Inc. |
Cell modulation nanocomposition, and methods of use
|
|
CA3190002A1
(en)
|
2014-02-14 |
2015-08-20 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
US20170081411A1
(en)
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
WO2015154012A1
(en)
|
2014-04-03 |
2015-10-08 |
Memorial Sloan-Kettering Cancer Center |
Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
|
|
IL296691B2
(en)
|
2014-04-25 |
2023-11-01 |
2Seventy Bio Inc |
MND promoter chimeric antigen receptors
|
|
KR102211120B1
(ko)
*
|
2014-05-15 |
2021-02-03 |
내셔널 유니버시티 오브 싱가포르 |
변형된 천연 살해 세포 및 그의 용도
|
|
CN106793780B
(zh)
|
2014-06-06 |
2020-05-26 |
蓝鸟生物公司 |
改善的t细胞组合物
|
|
CN106459916A
(zh)
|
2014-06-18 |
2017-02-22 |
乔治-施派尔-豪斯化学疗法研究所 |
作为细胞治疗剂的car‑表达nk‑92细胞
|
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
GB201415347D0
(en)
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
ES2808914T3
(es)
|
2014-09-04 |
2021-03-02 |
Stemcell Tech Inc |
Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK
|
|
EP3191507A1
(en)
|
2014-09-09 |
2017-07-19 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
MX378859B
(es)
|
2014-09-15 |
2025-03-11 |
Molmed Spa |
Receptores de antigenos quimericos.
|
|
US20170246217A1
(en)
|
2014-09-16 |
2017-08-31 |
Funndación Pública Andaluza Progreso y Salud |
Use of cord blood plasma to treat nk cell-mediated diseases and ifn-γ mediated diseases
|
|
MA41538A
(fr)
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
BR112017008696A2
(pt)
|
2014-10-27 |
2017-12-26 |
Univ Central Florida Res Found Inc |
métodos e composições para células exterminadoras naturais
|
|
WO2016073629A1
(en)
|
2014-11-05 |
2016-05-12 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
CN113736828A
(zh)
|
2014-11-05 |
2021-12-03 |
朱诺治疗学股份有限公司 |
用于转导及细胞处理的方法
|
|
KR20170075785A
(ko)
|
2014-11-05 |
2017-07-03 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포
|
|
EP3018200A1
(en)
|
2014-11-07 |
2016-05-11 |
Fondazione Matilde Tettamanti e Menotti de Machi Onlus |
Improved method for the generation of genetically modified cells
|
|
US11072644B2
(en)
|
2014-11-12 |
2021-07-27 |
Allogene Therapeutics, Inc. |
Inhibitory chimeric antigen receptors
|
|
KR102923234B1
(ko)
|
2014-12-19 |
2026-02-04 |
다나-파버 캔서 인스티튜트 인크. |
키메라 항원 수용체 및 이의 사용 방법
|
|
EP3240552A4
(en)
|
2014-12-31 |
2018-06-20 |
Anthrogenesis Corporation |
Natural killer cells and uses thereof
|
|
EP3240551A4
(en)
|
2014-12-31 |
2018-08-08 |
Anthrogenesis Corporation |
Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
US10377988B2
(en)
|
2015-01-23 |
2019-08-13 |
Musc Foundation For Research Development |
Cytokine receptor genes and the use thereof to enhance therapy
|
|
MA41433A
(fr)
|
2015-01-26 |
2017-12-05 |
Baylor College Medicine |
Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
|
|
JP6849600B6
(ja)
|
2015-01-29 |
2021-06-30 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
キメラ抗原受容体、組成物及び方法
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
GB201501936D0
(en)
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
|
US10765699B2
(en)
|
2015-02-06 |
2020-09-08 |
National University Of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
|
EP3253866B1
(en)
|
2015-02-06 |
2024-12-04 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
|
GB201503742D0
(en)
*
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CN107531805A
(zh)
|
2015-03-05 |
2018-01-02 |
弗雷德哈钦森癌症研究中心 |
免疫调节融合蛋白及其用途
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
US9777064B2
(en)
|
2015-03-17 |
2017-10-03 |
Chimera Bioengineering, Inc. |
Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
|
|
EP3270960A4
(en)
|
2015-03-20 |
2018-08-08 |
Bluebird Bio, Inc. |
Vector formulations
|
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
EP3270937A4
(en)
|
2015-03-26 |
2018-09-12 |
The Trustees Of Dartmouth College |
Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
|
|
CN108367057B
(zh)
|
2015-04-06 |
2022-11-22 |
赛通免疫股份有限公司 |
用于胶质母细胞瘤的egfr导向的car疗法
|
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
US20180092968A1
(en)
|
2015-04-23 |
2018-04-05 |
The Trustees Of The University Of Pennsylvania |
Compositions to disrupt protein kinase a anchoring and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
GB201507104D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507119D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507111D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507108D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507115D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
|
WO2016179684A1
(en)
|
2015-05-11 |
2016-11-17 |
University Health Network |
Method for expansion of double negative regulatory t cells
|
|
CN107921064A
(zh)
|
2015-05-28 |
2018-04-17 |
凯德药业股份有限公司 |
用于t细胞疗法的诊断方法
|
|
US20160361415A1
(en)
|
2015-05-28 |
2016-12-15 |
Armo Biosciences, Inc. |
Methods of Using Interleukin-10 for Treating Diseases and Disorders
|
|
MA43344A
(fr)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics Inc |
Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
|
|
WO2016197108A1
(en)
|
2015-06-05 |
2016-12-08 |
Board Of Regents, The University Of Texas System |
Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
|
|
CN107709552B
(zh)
|
2015-06-10 |
2022-05-13 |
南克维斯特公司 |
用于治疗癌症的修饰的nk-92细胞
|
|
TW202444897A
(zh)
|
2015-06-25 |
2024-11-16 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體(car)、組合物及其使用方法
|
|
US20180185434A1
(en)
|
2015-06-29 |
2018-07-05 |
The Johns Hopkins University |
Immune checkpoint chimeric antigen receptors therapy
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
EP3328994A4
(en)
|
2015-07-31 |
2019-04-17 |
Memorial Sloan-Kettering Cancer Center |
CD56-Faced Antigen-Binding Proteins and Uses Thereof
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
DK3331912T3
(da)
|
2015-08-04 |
2024-07-29 |
Xyphos Biosciences Inc |
Indsættelige variable fragmenter af antistoffer og modificerede a1-a2-domæner af nkg2d-ligander og ikke-naturlige nkg2d-ligander, der binder ikke-naturlige nkg2d-receptorer
|
|
KR20250008141A
(ko)
|
2015-08-07 |
2025-01-14 |
이미지냅 인코포레이티드 |
분자를 표적화하기 위한 항원 결합 구조체
|
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
CN107922498A
(zh)
|
2015-08-24 |
2018-04-17 |
塞勒克提斯公司 |
具有整合可控功能的嵌合抗原受体
|
|
EP3138905A1
(en)
|
2015-09-04 |
2017-03-08 |
Miltenyi Biotec GmbH |
Method for natural killer cell expansion
|
|
WO2017058753A1
(en)
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor, regulatory cells and methods of use
|
|
US11365391B2
(en)
|
2015-09-28 |
2022-06-21 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
|
CN108779174B
(zh)
|
2015-11-04 |
2022-11-29 |
希望之城公司 |
靶向her2的嵌合抗原受体
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
CN107109363A
(zh)
|
2015-11-09 |
2017-08-29 |
张明杰 |
增强对异常细胞杀伤力的方法和药物组合物
|
|
CN108884140B
(zh)
|
2015-12-03 |
2022-10-25 |
朱诺治疗学股份有限公司 |
修饰的嵌合受体及相关组合物和方法
|
|
JP6853514B2
(ja)
|
2015-12-27 |
2021-03-31 |
国立大学法人東海国立大学機構 |
炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
|
|
SG11201805186VA
(en)
|
2016-01-20 |
2018-07-30 |
Fate Therapeutics Inc |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
WO2017172981A2
(en)
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
CN105838677B
(zh)
|
2016-05-20 |
2019-07-02 |
杭州优善生物科技有限公司 |
一种高效扩增冷冻保存nk细胞的方法及其应用
|
|
EP3468994A1
(en)
|
2016-06-08 |
2019-04-17 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
|
CN105985931A
(zh)
|
2016-06-21 |
2016-10-05 |
黑龙江天晴干细胞股份有限公司 |
一种nk细胞体外扩增组合物及nk细胞扩增方法
|
|
CN109844099B
(zh)
|
2016-07-25 |
2024-01-02 |
美国政府(由卫生和人类服务部的部长所代表) |
产生经修饰的自然杀伤细胞的方法及使用方法
|
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Ltd |
Protein-based t-cell receptor knockdown
|
|
CN108148862B
(zh)
|
2016-12-05 |
2019-03-08 |
上海优卡迪生物医药科技有限公司 |
一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
|
|
MA46998A
(fr)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics Inc |
Production de cellules modifiées pour une thérapie cellulaire adoptive
|
|
CN110121505B
(zh)
*
|
2016-12-28 |
2023-08-01 |
株式会社绿十字细胞治疗 |
嵌合抗原受体和表达其的自然杀伤细胞
|
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
IL269553B2
(en)
|
2017-03-27 |
2025-10-01 |
Nat Univ Singapore |
Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
|
|
CN111247241A
(zh)
|
2017-08-10 |
2020-06-05 |
新加坡国立大学 |
T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法
|
|
CN109554348A
(zh)
|
2017-09-27 |
2019-04-02 |
亘喜生物科技（上海）有限公司 |
可诱导分泌抗cd47抗体的工程化免疫细胞
|
|
CA3079076A1
(en)
|
2017-10-18 |
2019-04-25 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Methods and compounds for improved immune cell therapy
|
|
CN107827990B
(zh)
|
2017-10-30 |
2020-07-10 |
河北森朗生物科技有限公司 |
一种多肽、编码其的核酸、其修饰的t淋巴细胞及其应用
|
|
EP3707248A4
(en)
|
2017-11-10 |
2021-08-18 |
Chineo Medical Technology Co., Ltd. |
MODIFIED IMMUNE CELLS AND THEIR USES
|
|
CN109971712B
(zh)
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
|
|
WO2019127215A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
US20210054409A1
(en)
|
2018-02-09 |
2021-02-25 |
National University Of Singapore |
Adhesion Receptor Constructs and Uses Thereof in Natural Killer Cell Immunotherapy
|
|
CN111801348A
(zh)
|
2018-02-09 |
2020-10-20 |
新加坡国立大学 |
活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
|
EP3759132A1
(en)
|
2018-03-02 |
2021-01-06 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
US11965176B2
(en)
|
2018-03-14 |
2024-04-23 |
Hunan Siweikang Therapeutics Co. Ltd |
Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
WO2020056045A1
(en)
|
2018-09-13 |
2020-03-19 |
Nkarta, Inc. |
Natural killer cell compositions and immunotherapy methods for treating tumors
|
|
CN111088231A
(zh)
|
2018-10-24 |
2020-05-01 |
艾生命序公司 |
Pd-l1抗体分泌的抗间皮素car-t细胞肿瘤免疫治疗
|
|
CA3120563A1
(en)
|
2018-11-26 |
2020-06-04 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
WO2020247392A1
(en)
|
2019-06-04 |
2020-12-10 |
Nkarta, Inc. |
Combinations of engineered natural killer cells and engineered t cells for immunotherapy
|
|
AU2020315213A1
(en)
|
2019-07-17 |
2022-02-03 |
National University Of Singapore |
Functional binders synthesized and secreted by immune cells
|
|
CN114450015A
(zh)
|
2019-07-31 |
2022-05-06 |
恩卡尔塔公司 |
用于天然杀伤细胞的增强的扩增和细胞毒性的方法和组合物
|
|
CA3164666A1
(en)
|
2020-01-13 |
2021-07-22 |
Kanya Lakshmi RAJANGAM |
Bcma-directed cellular immunotherapy compositions and methods
|
|
WO2021252804A1
(en)
|
2020-06-12 |
2021-12-16 |
Nkarta, Inc. |
Genetically modified natural killer cells for cd70-directed cancer immunotherapy
|
|
EP4204560A4
(en)
|
2020-09-02 |
2024-10-16 |
Nkarta, Inc. |
ENHANCED EXPANSION AND CYTOTOXICITY OF MODIFIED NATURAL KILLER CELLS AND RELATED USES
|
|
AU2021392809A1
(en)
|
2020-12-03 |
2023-07-20 |
Nkarta, Inc. |
Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
|
|
JP2025508050A
(ja)
|
2022-03-07 |
2025-03-21 |
ンカルタ・インコーポレイテッド |
Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞
|